In depth analysis of the market pattern of psoriasis in China in 2016

Psoriasis is a kind of hereditary chronic skin inflammation, which belongs to autoimmune chronic skin disease The global number of patients is about 125 million So far, psoriasis can not be cured, often accompanied by life With the increasing competition in China, the mental and psychological burden is increasing and the immune function is decreasing The incidence rate of psoriasis is increasing The number of people suffering from psoriasis is increasing According to the data of Dermatology and Venereology branch of Chinese Medical Association in 2016, the number of psoriasis patients in China has reached 6.5 million According to IMS data of rapid growth of global psoriasis drugs, the sales volume of global psoriasis drugs market in 2014 reached 7.49 billion US dollars It is estimated that the global sales volume of anti psoriasis drugs will exceed 10 billion US dollars in 2019 As we all know, there are some antibodies for psoriasis, such as adalimumab, infliximab and etanercept From February to July 2017, the new drugs brodalumab (siliq) and guselkumab (tremfya) were approved by the US FDA, and fresh blood was injected From 2009 to 2017, 8 new antibody drugs were approved, which increased the growth of new energy in the anti psoriasis drug market Become a very "money scene" area In recent years, according to the consensus of Chinese psoriasis experts (2014 Edition), glucocorticoids, vitamin D3 derivatives, tazarotene combination and sequential therapy are recommended as clinical first-line treatment Based on external treatment, the treatment principle is gradual For patients with mild to moderate psoriasis, topical therapy is the first choice The main terminal of anti psoriasis drugs in China is still stagnant in the field of chemical medicine and Chinese patent medicine Although infliximab, adamumumab and etanercept have been listed in China, the clinical use of anti psoriasis antibodies is still rare The sample data shows that in 2016, the market of 18 anti psoriasis chemical drugs in public hospitals in key cities in China was RMB 259 million, an increase of 43.59% over the previous year It is predicted that the market scale of psoriasis drugs in China will reach 5 billion in 2017 In 2016, the varieties of TOP10 were halonasone ointment, Calcipotriol Ointment, Cape three alcohol betamethasone ointment and gel, budesonide ointment, fluticasone ointment, Pyrithione Zinc Aerosol, compound chlorphenasol ointment, acaveric acid A capsules, Tacalcitol Ointment, compound Amino-polypeptide Tablets, half of which were exclusive varieties into the hospital TOP5 has a good performance The LEO Pharma of the Danish Pharma kappa three betamethasone ointment and the gel "CME" become a straight up variety The main drugs for psoriasis in China are the derivatives of vitamin D3, such as calcipotriol, tacalcitol and calcitriol Active vitamin D3 can combine with vitamin D3 receptor in vivo, inhibit the abnormal proliferation of skin keratinocytes, induce the normal keratinization of cells, and inhibit the activation of lymphocytes, so as to flatten the plaque of psoriasis and alleviate the inflammation of skin lesions It is understood that carbotrianol and tacassinol have become the first-line drugs for the treatment of psoriasis vulgaris The imported Kappo three alcohol series of imported drugs mainly include the Danish LEO's carbol three alcohol "Dali Shi", compound carbol three alcohol betamethasone ointment "De Fu Bao" and gel "samel", as well as Hongkong Australia and America "Ao Qing" and German herson varieties The exclusive variety of domestic carbotriol is the star product "jindiyin" of Chongqing Huabang In 2016, the market scale of public hospitals in key cities in China was 53.88 million yuan, up 1.07% year on year In terms of market share, Leo Denmark accounts for 81.3%, Australia and the United States of Hong Kong accounts for 17.58%, and China State Chongqing accounts for 1.13% Carbotriol and its compound preparations account for half of the market of anti psoriasis drugs The growth of zinc pyrithione slowed down The anti psoriasis drug pyrithion zinc is imported from abroad Its core function can effectively interfere with the synthesis of scurf protein, inhibit its abnormal division and proliferation, so as to inhibit the epidermis hyperplasia and exfoliation, reduce the production of scales, at the same time, it can inhibit the inflammation and bacteriostasis, inhibit the epidermis such as Sporotrichum, improve the abnormal secretion of sebum The cell growth factors and moisturizing ingredients in cream include It can promote the rapid repair of epidermis Because thiophanate zinc is only aimed at abnormal scurf protein, it will not affect normal cells, and the series of products do not contain hormones, so it has no side effects and will not lead to recurrence In 2009, China approved the listing of zinc pyrithione aerosol of cheminova in China, with the trade name of skin cap Thiophanate zinc can effectively inhibit the excessive proliferation of epidermal keratinocytes, inhibit the excessive secretion of sebum, have bacteriostatic effect, reduce the inflammatory reaction of skin lesions, alleviate the itching and pain of skin lesions In 2016, the available market of public hospitals in key cities in China was 8.21 million yuan, which showed ups and downs in recent years, mainly because domestic generic drugs were not listed and lacked competitiveness Vitamin A acids are a group of compounds with similar structure to natural vitamin A The main varieties of Avia and Avia ester are oral drugs for the treatment of psoriasis Tazarotene, a receptor selective third-generation retinoic acid, is the first topical therapy for mild to moderate psoriasis The mechanism of action of retinoids is to regulate the abnormal differentiation of keratinocytes, inhibit their over proliferation, affect the immune system and inflammatory process, and change the adhesion between target cells It is an effective drug for the treatment of plaque, pustular, palmoplantar, drip and erythroderma psoriasis Avia has a short half-life and low lipophilicity It is an oral drug for psoriasis treatment market According to the Chinese psoriasis treatment guidelines, Avia is safe and can be used for a long time without time limit, which is conducive to continuous treatment and improve the efficacy There are two suppliers of Avia in the domestic market, Fangxi of Chongqing Huabang Pharmaceutical Co., Ltd and neotagason of Actavis group PTC EHF The combination of Avia and PUVA or UVB can improve the efficacy and safety of plaque psoriasis Avia, methotrexate or cyclosporine A can improve the therapeutic effect on severe and systemic purulent psoriasis In 2016, Avia in public hospitals in key cities in China was 6.56 million yuan, down 7.21% year on year The domestic anti-psoriasis IL-17A inhibitor has seen the dawn in foreign countries The clinical use of anti-psoriasis drugs has made a rapid progress towards antibody biological drugs, but China has not yet opened a green channel in this regard The shr-1314 developed by Jiangsu Hengrui is a human-derived interleukin-17A (IL-17A) inhibitor, which challenges the proinflammatory cytokines It is understood that shr-1314 injection has obtained the approval document for clinical trial of drugs (2016l05608) approved and issued by the drug administration Shr-1314 is a humanized monoclonal antibody drug independently developed by Hengrui medicine It can specifically combine with IL-17A to inhibit the production of gro α and other cytokines, and block the signal transduction pathway It is mainly used in the treatment of psoriasis It is planned to develop indications such as Crohn's disease, multiple sclerosis, asthma, lupus erythematosus, rheumatoid arthritis, etc Under the process of increasing clinical trials, it is expected to be approved for listing in advance So far, five kinds of proinflammatory cytokines, including stelara, cosentyx, taltz, siliq and tremfya, have been listed in the world It is expected that by 2019, domestic antibody bioengineering drugs will enter the field of anti psoriasis.